Compare JPMorgan Equity Premium Income ETF (JEPI) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Equity Premium Income ETF vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? JPMorgan Equity Premium Income ETF trades at $56.96 (market cap $45.63B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: JPMorgan Equity Premium Income ETF is far larger — about 46.7× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, JPMorgan Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Equity Premium Income ETF for 58 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| JEPI | MRVI | |
|---|---|---|
Market Cap | $45.63B | $977.37M |
Volume | 4,550,946 | 2,742,564 |
Sector | Income / Options Overlay | Health |
52-Week High | $59.88 | $9.00 |
52-Week Low | $55.29 | $2.83 |
Typical Hold Time | 58 Days | 0 Days |
Enterprise Value | — | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JEPI trades at $56.93, showing minimal daily movement with a slight decline of 0.05%. The ETF maintains a bullish technical outlook with strong moving average signals, though oscillators suggest neutral momentum. Recent dividend distributions of $0.34-$0.37 demonstrate consistent income generation, while financial media coverage highlights JEPI's role in income-focused portfolios and its appeal to retirees seeking monthly distributions.
JEPI presents as a stable income vehicle with reliable dividend payments, though valuation metrics remain unavailable for fundamental assessment. The ETF's covered call strategy provides downside protection but may limit upside potential during strong market rallies. Key risks include interest rate sensitivity and the trade-off between income generation and capital appreciation in rising markets.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About JPMorgan Equity Premium Income ETF
JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
